| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 142.23 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Tocilizumab (TCZ) is a humanized immunoglobulin G1 monoclonal antibody that targets and inhibits the interleukin-6 (IL-6) receptor. As a selective inhibitor of this cytokine, TCZ offers a targeted approach in managing inflammatory conditions. Given its specificity and potential therapeutic benefits, this article aims to provide a comprehensive summary of the efficacy and safety of TCZ in the treatment of RA.
Descrição
Palavras-chave
Immune system Tumor immunology Autoimmune disease
Contexto Educativo
Citação
Silva, D., Moreira, F., & Santos, M. (2025). Efficacy and safety of Tocilizumab in the treatment of Rheumatoid Arthritis: An umbrella review. 34 (1), 10, 11. https://www.mdpi.com/2673-9992/34/1/1
Editora
MDPI
